This analysis shows that chemotherapy with sugemalimab lacks cost-effectiveness in advanced gastric cancer, indicating a need for price negotiations.
At current prices, sugemalimab plus CAPOX is not cost-effective as a first-line treatment for advanced GC/GEJC in China. It is essential to adopt a combination of targeted patient selection, price negotiation, and broader PAP access to bring the ICER below the WTP threshold. These findings inform reimbursement negotiations and highlight the need for stratified pricing strategies to optimize accessibility in economically diverse populations.
No takes yet. Share an insight, caveat, or question.
Zhu et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: